JP2009523460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523460A5 JP2009523460A5 JP2008551864A JP2008551864A JP2009523460A5 JP 2009523460 A5 JP2009523460 A5 JP 2009523460A5 JP 2008551864 A JP2008551864 A JP 2008551864A JP 2008551864 A JP2008551864 A JP 2008551864A JP 2009523460 A5 JP2009523460 A5 JP 2009523460A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom10
- ligand
- variable domain
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims 117
- 102000003816 Interleukin-13 Human genes 0.000 claims 70
- 108090000176 Interleukin-13 Proteins 0.000 claims 70
- 108060003951 Immunoglobulin Proteins 0.000 claims 53
- 102000018358 immunoglobulin Human genes 0.000 claims 53
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 102000004388 Interleukin-4 Human genes 0.000 claims 28
- 108090000978 Interleukin-4 Proteins 0.000 claims 28
- 229940028885 interleukin-4 Drugs 0.000 claims 28
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 17
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 17
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 15
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 8
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 230000001629 suppression Effects 0.000 claims 8
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 7
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 102000019207 human interleukin-13 Human genes 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000013566 allergen Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 241000238876 Acari Species 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 102000055229 human IL4 Human genes 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000013573 pollen allergen Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76170806P | 2006-01-24 | 2006-01-24 | |
| PCT/GB2007/000228 WO2007085815A2 (en) | 2006-01-24 | 2007-01-24 | Ligands that bind il-4 and/or il-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523460A JP2009523460A (ja) | 2009-06-25 |
| JP2009523460A5 true JP2009523460A5 (https=) | 2009-11-05 |
Family
ID=38028503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551863A Pending JP2009523459A (ja) | 2006-01-24 | 2007-01-24 | 天然の連結部を含有する融合タンパク質 |
| JP2008551864A Pending JP2009523460A (ja) | 2006-01-24 | 2007-01-24 | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551863A Pending JP2009523459A (ja) | 2006-01-24 | 2007-01-24 | 天然の連結部を含有する融合タンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20110159003A1 (https=) |
| EP (2) | EP2441838A3 (https=) |
| JP (2) | JP2009523459A (https=) |
| KR (1) | KR20080098382A (https=) |
| CN (1) | CN101578298A (https=) |
| AU (1) | AU2007209202A1 (https=) |
| BR (1) | BRPI0710572A2 (https=) |
| CA (1) | CA2636854A1 (https=) |
| CR (1) | CR10179A (https=) |
| EA (1) | EA200801515A1 (https=) |
| IL (1) | IL192572A0 (https=) |
| MA (1) | MA30175B1 (https=) |
| NO (1) | NO20082942L (https=) |
| TW (2) | TW200804593A (https=) |
| WO (1) | WO2007085815A2 (https=) |
| ZA (1) | ZA200806202B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| WO2009138413A1 (en) * | 2008-05-15 | 2009-11-19 | Domantis Limited | Single domain antibodies that bind il-13 |
| TW200812616A (en) * | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2195342A1 (en) * | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2036980A1 (de) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2017201007B2 (en) * | 2007-10-15 | 2018-12-13 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
| EP2220115A2 (en) * | 2007-12-13 | 2010-08-25 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| WO2009089295A2 (en) * | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
| BRPI0906261A2 (pt) * | 2008-03-31 | 2015-07-07 | Genentech Inc | "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| CA2737241C (en) * | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| AU2009306424A1 (en) * | 2008-10-21 | 2010-04-29 | Domantis Limited | Ligands that have binding specificity for DC-SIGN |
| ES2705714T3 (es) | 2008-10-31 | 2019-03-26 | Janssen Biotech Inc | Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones |
| KR20110092328A (ko) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Ｉｌ-13에 결합하는 리간드 |
| AU2009324354B2 (en) | 2008-12-10 | 2016-04-14 | Ablynx Nv | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
| BRPI1016061A2 (pt) * | 2009-05-28 | 2016-09-13 | Glaxo Group Ltd | "proteína de ligação de antígeno, célula hospedeira transfectada ou transformada recombinante, composição farmacêutica, método de tratamento de um paciente humano, uso de uma proteína de ligação de antígeno, método para a redução da agregação de um domínio variável simples de imunoglobulina, vk dab humano derivado de uma estrutura da linha germinativa, e, domínio variável simples de imunoglobulina." |
| JP5901517B2 (ja) | 2009-05-28 | 2016-04-13 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 抗原結合性タンパク質 |
| WO2011006915A2 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| KR20120063475A (ko) | 2009-07-29 | 2012-06-15 | 글락소 그룹 리미티드 | 항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체 |
| EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| DK2533761T3 (da) * | 2010-02-11 | 2019-06-24 | Ablynx Nv | Fremgangsmåder og sammensætninger til fremstilling af aerosoler |
| US8569227B2 (en) | 2010-04-30 | 2013-10-29 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
| WO2012093125A1 (en) | 2011-01-06 | 2012-07-12 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
| TWI719112B (zh) | 2011-03-16 | 2021-02-21 | 賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| HUE038848T2 (hu) | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| JP6440496B2 (ja) | 2011-09-27 | 2018-12-19 | ヤンセン バイオテツク，インコーポレーテツド | 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド |
| US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| EP2863948B1 (en) * | 2012-06-22 | 2018-10-24 | Cytomx Therapeutics Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| WO2014030780A1 (en) | 2012-08-22 | 2014-02-27 | Mogam Biotechnology Research Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
| RU2711478C2 (ru) * | 2013-12-17 | 2020-01-17 | ЭмЭйчЭс КЕА-ИННОВЕЙШН ЭлЭлСи | Композиции и способы борьбы с накоплением жировой ткани |
| US11066467B2 (en) | 2013-12-17 | 2021-07-20 | Mhs Care-Innovation Llc | Compositions and methods for treating ischemic heart disease |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| CA2943326A1 (en) * | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
| US10561805B2 (en) | 2014-10-10 | 2020-02-18 | Ablynx N.V. | Methods of treating RSV infections |
| EP3204095B8 (en) | 2014-10-10 | 2019-07-10 | Ablynx N.V. | Inhalation device for use in aerosol therapy of respiratory diseases |
| AU2015346150B2 (en) | 2014-11-14 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| CN109311968A (zh) | 2016-05-02 | 2019-02-05 | 埃博灵克斯股份有限公司 | 治疗rsv感染 |
| JP6293829B2 (ja) * | 2016-08-05 | 2018-03-14 | モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| CN110225770B (zh) | 2016-12-14 | 2022-04-26 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| CN108855003B (zh) * | 2018-06-28 | 2021-01-05 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| EP3930754A4 (en) | 2019-02-27 | 2023-08-16 | Zhejiang Nanomab Technology Center Co. Ltd. | HIGH-THROUGHPUT SEQUENCE-BASED PROCEDURE FOR GENERATION OF CAMELID ANTIBODIES TO COVER WIDE EPITOPES WITH HIGH RESOLUTION |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN113527488B (zh) | 2020-04-22 | 2026-04-17 | 迈威(上海)生物科技股份有限公司 | 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| JP2023524997A (ja) * | 2020-05-06 | 2023-06-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 |
| EP4323008A4 (en) | 2021-04-14 | 2026-02-25 | Aro Biotherapeutics Company | FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| US20250388663A1 (en) * | 2022-08-17 | 2025-12-25 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| CA2130436C (en) * | 1992-02-19 | 2001-04-10 | John S. Abrams | Cloning and expression of humanized monoclonal antibodies against human interleukin-4 |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| WO2000078334A1 (en) * | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| EP1400534B1 (en) * | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
| EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| PL3718564T3 (pl) * | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Nowe przeciwciała anty-IL 13 i ich zastosowania |
| EP1723173B1 (en) * | 2004-02-27 | 2008-05-14 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypeptides and therapeutic uses thereof |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| WO2006023460A2 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
-
2007
- 2007-01-24 EP EP11157601.3A patent/EP2441838A3/en not_active Withdrawn
- 2007-01-24 BR BRPI0710572-0A patent/BRPI0710572A2/pt not_active IP Right Cessation
- 2007-01-24 EP EP07705003A patent/EP1976882A2/en not_active Withdrawn
- 2007-01-24 TW TW096102778A patent/TW200804593A/zh unknown
- 2007-01-24 KR KR1020087020811A patent/KR20080098382A/ko not_active Ceased
- 2007-01-24 CN CNA2007800097556A patent/CN101578298A/zh active Pending
- 2007-01-24 CA CA002636854A patent/CA2636854A1/en not_active Abandoned
- 2007-01-24 US US12/223,005 patent/US20110159003A1/en not_active Abandoned
- 2007-01-24 JP JP2008551863A patent/JP2009523459A/ja active Pending
- 2007-01-24 JP JP2008551864A patent/JP2009523460A/ja active Pending
- 2007-01-24 TW TW096102774A patent/TW200740843A/zh unknown
- 2007-01-24 EA EA200801515A patent/EA200801515A1/ru unknown
- 2007-01-24 WO PCT/GB2007/000228 patent/WO2007085815A2/en not_active Ceased
- 2007-01-24 AU AU2007209202A patent/AU2007209202A1/en not_active Abandoned
-
2008
- 2008-05-15 US US12/152,903 patent/US20090060916A1/en not_active Abandoned
- 2008-07-02 IL IL192572A patent/IL192572A0/en unknown
- 2008-07-02 NO NO20082942A patent/NO20082942L/no not_active Application Discontinuation
- 2008-07-16 ZA ZA200806202A patent/ZA200806202B/xx unknown
- 2008-07-24 CR CR10179A patent/CR10179A/es unknown
- 2008-07-25 MA MA31143A patent/MA30175B1/fr unknown
-
2009
- 2009-05-13 US US12/992,718 patent/US20120093830A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523460A5 (https=) | ||
| JP7817994B2 (ja) | Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| JP7641968B2 (ja) | Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| RU2427589C2 (ru) | Антитела против интерлейкина-13 человека и их применение | |
| CN113527485B (zh) | 抗人白细胞介素-4受体α抗体及其制备方法和应用 | |
| EP3808774B1 (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| JP2008502366A5 (https=) | ||
| JP5767625B2 (ja) | Ｉｌ−１７ｂｒに対する抗体 | |
| JP2009519011A5 (https=) | ||
| JP2009517069A5 (https=) | ||
| CN110357963A (zh) | 抗人st2抗体及其用途 | |
| JP7608592B2 (ja) | ヘテロ二量体Ｆｃ融合タンパク質、並びに関連の組成物、用途及び方法 | |
| WO2022117079A1 (zh) | 结合胸腺基质淋巴细胞生成素的抗体及其应用 | |
| WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
| AU2023407259A1 (en) | Multivalent and multispecific cytokine antagonists | |
| CN116783214A (zh) | 包含靶向il-13和ox40l的免疫球蛋白单可变结构域的多肽 | |
| CN117843776B (zh) | 抗体分子、核酸、制药用途及炎性疾病治疗方法 | |
| RU2825460C1 (ru) | Антитела к TSLP человека и их применение | |
| TW202611079A (zh) | Ｃｄ８結合多肽及使用方法 | |
| CN119855828A (zh) | 抗TfR1的单域抗体及其用途 | |
| WO2025221933A1 (en) | Antibodies and polypeptides comprising variant fc regions | |
| HK40096780A (zh) | 抗人il-4ra的抗体及其用途 |